New inhaled therapy targets Hard-to-Treat cystic fibrosis mutation

NCT ID NCT06429176

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called SPL84 in adults with cystic fibrosis who have a specific genetic mutation (3849+10kb C->T). The drug is inhaled weekly for 9 to 12 weeks. Researchers want to see if it is safe and if it can improve lung function. Some participants will receive a placebo instead of the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Locations

  • Boston Children'S Hospital

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National Jewish Health

    RECRUITING

    Denver, Colorado, 80206, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Southern California

    RECRUITING

    Los Angeles, California, 90033, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••